跳至主要内容
临床试验/NCT04448314
NCT04448314已完成不适用

Study to Evaluate the Usability of PointCheck, a Novel Optical Technology for Screening Non-Invasively Severe Neutropenia

Leuko Labs, Inc.3 个研究点 分布在 1 个国家目标入组 94 人开始时间: 2020年2月11日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
94
试验地点
3
主要终点
PointCheck's Usability

研究概览

简要总结

This a study about the usability of PointCheck a novel non-invasive technology for monitoring chemotherapy-induced neutropenia. The study will include patients with cancer visiting the outpatient hematology clinic for their standard of care chemotherapy administration. A final sample size of 60 oncologic outpatients will be enrolled and studied with the technology.

The main objective is to evaluate the usability of PointCheck. Secondary outcomes include a preliminary assessment of PointCheck diagnostic accuracy and precision.

For this, study subjects will be tested twice with PointCheck during the same session and the usability in an at-home simulated environment by naïve users will be evaluated.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Other

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Study subjects must be able to understand the purpose and risks of the study and to provide signed and dated informed consent and authorization to use confidential health information in accordance with national and local subject privacy regulations.
  • Male or Female aged 18 years or above
  • Diagnosed with hematological malignancy (e.g., lymphoma, myeloma) or breast cancer.
  • Scheduled active treatment with cytotoxic chemotherapy with an associated high/intermediate risk of neutropenia.
  • Able (in the Investigators opinion) and willing to comply with all study requirements.
  • Exclusion Criteria
  • Participants with amputations, congenital malformations or any severe abnormalities of the hands as determined by the investigator.
  • Participants with a history of vasculitis, Raynaud syndrome, scleroderma, mixed connective tissue disease or any other rheumatologic systemic condition that could produce microcirculatory changes in the nailfold.
  • Participants with circulating tumor cells in previous or current lab determinations.
  • Unstable participants or participants with hypotension (systolic blood pressure <90 and diastolic blood pressure < 60mmHg).
  • Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
  • Other unspecified reasons that, in the opinion of the Investigator or Sponsor, make the subject unsuitable for enrolment.

排除标准

  • 未提供

结局指标

主要结局

PointCheck's Usability

时间窗: Up to three-weeks

To gather data with the ultimate goal of determining the usability of the proposed non-invasive method measured by the the number and % of user errors (globally and per error type) observed in the clinic visits. In addition, the number and % of users successfully completing the test without errors will be measured.

System Usability Scale (0-100 higher scores indicate better usability)

时间窗: Up to three-weeks

To confirm the usability of the system using the System Usability Scale

次要结局

  • PointCheck's Precision(Up to three-weeks)
  • PointCheck's Utility(Up to three-weeks)
  • PointCheck's Safety: total number (%) of AEs and SAEs(Up to three-weeks)
  • PointCheck's Accuracy(Up to three-weeks)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验